Literature DB >> 23561437

To be immunogenic, or not to be: that's the iPSC question.

Shin Kaneko1, Shinya Yamanaka.   

Abstract

The unexpected finding that autologous induced pluripotent stem cell (iPSC)-derived teratomas are immunogenic in syngeneic hosts sparked pessimism over their therapeutic potential; however, two recent reports (Guha et al., 2013 and Araki et al., 2013; the latter in this issue of Cell stem cell) contradict previous findings, showing no immunogenicity of in vitro differentiated syngeneic iPS-derived cells and supporting their safety.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID： 23561437     DOI： 10.1016/j.stem.2013.03.008

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  30 in total

Review 1.  Induced pluripotent stem cell (iPSCs) and their application in immunotherapy.

Authors:  Zhengping Jiang; Yanmei Han; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2013-12-16       Impact factor: 11.530

Review 2.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 3.  The bioengineered kidney: science or science fiction?

Authors:  Leif Oxburgh; Thomas J Carroll
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 4.  New strategies for improving stem cell therapy in ischemic heart disease.

Authors:  Peisen Huang; Xiaqiu Tian; Qing Li; Yuejin Yang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 5.  Transflammation: Innate immune signaling in nuclear reprogramming.

Authors:  Shu Meng; Palas Chanda; Rajarajan A Thandavarayan; John P Cooke
Journal:  Adv Drug Deliv Rev       Date:  2017-09-13       Impact factor: 15.470

6.  Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord.

Authors:  Dhruv Sareen; Geneviève Gowing; Anais Sahabian; Kevin Staggenborg; Renée Paradis; Pablo Avalos; Jessica Latter; Loren Ornelas; Leslie Garcia; Clive N Svendsen
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

7.  Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead.

Authors:  Holly N Cukier; Jimmy El Hokayem; Derek M Dykxhoorn
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-10-25

Review 8.  Ectopic transplantation sites for cell-based therapy.

Authors:  Aaron D DeWard; Junji Komori; Eric Lagasse
Journal:  Curr Opin Organ Transplant       Date:  2014-04       Impact factor: 2.640

9.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

Review 10.  Directed differentiation of pluripotent stem cells to kidney cells.

Authors:  Albert Q Lam; Benjamin S Freedman; Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2014-06-13       Impact factor: 5.299
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.